• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发和优化基于假病毒的敏感检测方法,用于检测 HIV-1 中和抗体,使用 A3R5 细胞。

Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.

机构信息

a Division of HIV/AIDS and Sex-transmitted Virus Vaccines , National Institutes for Food and Drug Control (NIFDC) , Beijing , China.

b Beijing You'an Hospital, Capital Medical University , Beijing , China.

出版信息

Hum Vaccin Immunother. 2018 Jan 2;14(1):199-208. doi: 10.1080/21645515.2017.1373922. Epub 2017 Oct 18.

DOI:10.1080/21645515.2017.1373922
PMID:28933644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5791569/
Abstract

Sensitive assays for HIV-1 neutralizing antibody detection are urgently needed for vaccine immunogen optimization and identification of protective immune response levels. In this study, we developed an easy-to-use HIV-1 pseudovirus neutralization assay based on a human CD4 lymphoblastoid cell line A3R5 by employing a high efficient pseudovirus production system. Optimal conditions for cell counts, infection time, virus dose and concentration of DEAE-dextran were tested and identified. For T-cell line-adapted tier 1 virus strains, significantly higher inhibitory efficiency was observed for both monoclonal neutralizing antibody (4 fold) and plasma (2 fold) samples in A3R5 than those in TZM-bl assay. For circulating tier 2 strains, the A3R5 pseudovirus assay showed even much higher sensitivity for both neutralizing antibody (10 fold) and plasma (9 fold) samples. When sequential neutralizing antibody seroconverting samples were tested in both A3R5 and TZM-bl assays, the seroconverting points could be detected earlier for tier 1 (15.7 weeks) and tier 2 (68.3 weeks) strains in A3R5 assay respectively. The high sensitive pseudovirus assay using more physiological target cells could serve as an alternative to the TZM-bl assay for evaluation of vaccine-induced neutralizing antibodies and identification of the correlates of protection.

摘要

迫切需要灵敏的 HIV-1 中和抗体检测分析方法,用于疫苗免疫原优化和鉴定保护性免疫反应水平。在这项研究中,我们开发了一种基于人 CD4 淋巴母细胞系 A3R5 的易于使用的 HIV-1 假病毒中和测定法,该方法采用了高效的假病毒生产系统。对细胞计数、感染时间、病毒剂量和 DEAE-葡聚糖浓度的最佳条件进行了测试和鉴定。对于 T 细胞系适应的 1 级病毒株,在 A3R5 中观察到单克隆中和抗体(4 倍)和血浆(2 倍)样本的抑制效率明显高于 TZM-bl 测定法。对于循环的 2 级株,A3R5 假病毒测定法对中和抗体(10 倍)和血浆(9 倍)样本的敏感性更高。当在 A3R5 和 TZM-bl 测定法中检测连续的中和抗体血清转换样本时,A3R5 测定法可分别更早地检测到 1 级(15.7 周)和 2 级(68.3 周)株的血清转换点。使用更具生理意义的靶细胞的高灵敏度假病毒测定法可替代 TZM-bl 测定法,用于评估疫苗诱导的中和抗体,并鉴定保护性相关因素。

相似文献

1
Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.开发和优化基于假病毒的敏感检测方法,用于检测 HIV-1 中和抗体,使用 A3R5 细胞。
Hum Vaccin Immunother. 2018 Jan 2;14(1):199-208. doi: 10.1080/21645515.2017.1373922. Epub 2017 Oct 18.
2
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.优化和验证 A3R5 细胞中 HIV-1 的中和抗体检测方法。
J Immunol Methods. 2014 Jul;409:147-60. doi: 10.1016/j.jim.2014.02.013. Epub 2014 Mar 6.
3
Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China.优化并能力验证一种基于假病毒的检测方法,用于检测中国的 HIV-1 中和抗体。
J Virol Methods. 2012 Nov;185(2):267-75. doi: 10.1016/j.jviromet.2012.07.011. Epub 2012 Jul 13.
4
Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.广泛中和抗体及抗病毒试剂单独或联合使用对游离型和细胞间HIV-1传播的抑制作用
J Virol. 2015 Aug;89(15):7813-28. doi: 10.1128/JVI.00783-15. Epub 2015 May 20.
5
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.在人源 CD4+/CXCR4+/CCR5+T 淋巴母细胞系测定系统中检测 HIV-1 中和抗体。
PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.
6
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.RV144 和 Vax003 HIV-1 疫苗功效试验中的中和抗体反应的幅度和广度。
J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.
7
Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1.针对二价CM235/SF2 gp120疫苗接种的特异性抗体反应:检测对1型E亚型(CRF01.AE)HIV的同源和异源中和抗体。
AIDS Res Hum Retroviruses. 2003 Sep;19(9):807-16. doi: 10.1089/088922203769232601.
8
Impact of host cell variation on the neutralization of HIV-1 in vitro.宿主细胞变异对 HIV-1 体外中和的影响。
Curr Opin HIV AIDS. 2009 Sep;4(5):400-7. doi: 10.1097/COH.0b013e32832edc50.
9
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.用于对感染和疫苗接种的抗体反应进行标准化评估的HIV-1中和试验特性的最新进展。
Virology. 2008 Jun 5;375(2):315-20. doi: 10.1016/j.virol.2008.02.007. Epub 2008 Mar 25.
10
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.国际技术转移:符合 GCLP 的 HIV-1 中和抗体检测用于人体临床试验。
PLoS One. 2012;7(1):e30963. doi: 10.1371/journal.pone.0030963. Epub 2012 Jan 27.

引用本文的文献

1
Applying Flow Virometry to Study the HIV Envelope Glycoprotein and Differences Across HIV Model Systems.应用流场病毒仪研究 HIV 包膜糖蛋白和不同的 HIV 模型系统。
Viruses. 2024 Jun 9;16(6):935. doi: 10.3390/v16060935.
2
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.HIV-1 gp41 N-端七肽重复区三聚体稳定化肽免疫原及其作为 HIV-1 疫苗候选物的用途。
Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2317230121. doi: 10.1073/pnas.2317230121. Epub 2024 May 20.
3
Assays Based on Pseudotyped Viruses.基于假型病毒的检测方法。
Adv Exp Med Biol. 2023;1407:29-44. doi: 10.1007/978-981-99-0113-5_2.
4
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.吸入型腺病毒载体 COVID-19 疫苗异源加强针产生了更多针对不同 SARS-CoV-2 变体的中和抗体。
Emerg Microbes Infect. 2022 Dec;11(1):2689-2697. doi: 10.1080/22221751.2022.2132881.
5
Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng.基于慢病毒载体的具有双报告基因的新冠病毒假病毒的制备与表征:韩国红参抗新冠病毒作用的评估
J Ginseng Res. 2023 Jan;47(1):123-132. doi: 10.1016/j.jgr.2022.07.003. Epub 2022 Jul 15.
6
SARS-CoV-2-specific CD4 T cells are associated with long-term persistence of neutralizing antibodies.SARS-CoV-2 特异性 CD4 T 细胞与中和抗体的长期持久性相关。
Signal Transduct Target Ther. 2022 Apr 23;7(1):132. doi: 10.1038/s41392-022-00978-0.
7
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.异源加强接种第三剂冠状病毒疾病重组亚单位疫苗可提高针对不同严重急性呼吸综合征冠状病毒 2 变体的中和抗体和 T 细胞免疫。
Emerg Microbes Infect. 2022 Dec;11(1):829-840. doi: 10.1080/22221751.2022.2048969.
8
Overview of Neutralizing Antibodies and Their Potential in COVID-19.中和抗体及其在新冠病毒肺炎中的潜力概述
Vaccines (Basel). 2021 Nov 23;9(12):1376. doi: 10.3390/vaccines9121376.
9
A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2.一种多功能中和抗体偶联纳米颗粒抑制和失活 SARS-CoV-2。
Adv Sci (Weinh). 2022 Jan;9(2):e2103240. doi: 10.1002/advs.202103240. Epub 2021 Nov 10.
10
Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.基于刺突蛋白的进化动态和特定病毒突变对 SARS-CoV-2 全球传播的特征分析。
Infect Dis Poverty. 2021 Aug 21;10(1):112. doi: 10.1186/s40249-021-00895-4.

本文引用的文献

1
Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system.基于高滴度假病毒系统的体外和体内狂犬病病毒中和测定法的建立。
Sci Rep. 2017 Feb 20;7:42769. doi: 10.1038/srep42769.
2
Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.基于三色假病毒的检测人乳头瘤病毒中和抗体检测方法的开发
Viruses. 2016 Apr 25;8(4):107. doi: 10.3390/v8040107.
3
Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.在HIV-1感染的最初几个月内检测广泛中和活性。
J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.
4
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.向猕猴体内被动转移适度滴度的强效且具有广泛中和作用的抗HIV单克隆抗体,可阻断猴免疫缺陷病毒感染。
J Exp Med. 2014 Sep 22;211(10):2061-74. doi: 10.1084/jem.20132494. Epub 2014 Aug 25.
5
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.优化和验证 A3R5 细胞中 HIV-1 的中和抗体检测方法。
J Immunol Methods. 2014 Jul;409:147-60. doi: 10.1016/j.jim.2014.02.013. Epub 2014 Mar 6.
6
Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.精英中和者体内广泛反应性HIV-1中和活性的早期发展
AIDS. 2014 May 15;28(8):1237-40. doi: 10.1097/QAD.0000000000000228.
7
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.慢性HIV-1感染期间广泛中和抗体反应的流行率。
AIDS. 2014 Jan 14;28(2):163-9. doi: 10.1097/QAD.0000000000000106.
8
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.在人源 CD4+/CXCR4+/CCR5+T 淋巴母细胞系测定系统中检测 HIV-1 中和抗体。
PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.
9
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.优化和验证 TZM-bl 测定法,用于标准化评估抗 HIV-1 的中和抗体。
J Immunol Methods. 2014 Jul;409:131-46. doi: 10.1016/j.jim.2013.11.022. Epub 2013 Dec 1.
10
Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China.优化并能力验证一种基于假病毒的检测方法,用于检测中国的 HIV-1 中和抗体。
J Virol Methods. 2012 Nov;185(2):267-75. doi: 10.1016/j.jviromet.2012.07.011. Epub 2012 Jul 13.